Administration of DEP-1 antisense oligonucleotides (ASOs) reduced DEP-1 expression and activity in metabolic tissues. A-C: Quantitative real-time PCR was performed for DEP-1, PTP1B and insulin receptor (IR) in liver, skeletal muscle and adipose tissue mRNA from mice subjected to either control ASO or DEP-1 ASO treatment. Gene expression was normalized to expression of the housekeeping gene 18S and is shown as mean ± standard error of the mean; (n = 8–9 per group). D-F: DEP-1 activity was measured using a dephosphorylation assay of a 32P labeled phosphopeptide after immunoprecipitation of DEP-1 in liver, skeletal muscle and adipose tissue from mice subjected to either control ASO or DEP-1 ASO treatment. DEP-1 activity in control ASO mice were set to 100%; (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001.